1year Fin -> 1 year DUT + oral Minox; No results :( Finasteride/Dutasteride 6/25/2026
The user tried finasteride, dutasteride, and oral minoxidil for hair loss with no success and was diagnosed with androgenetic alopecia. They are considering increasing dosages and trying other treatments like RU58841, GHK-CU, and clascoterone, while seeking further medical opinions.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity 24M seeking help for aggressive androgenetic alopecia - "nuke" stack?
A 24-year-old male with aggressive androgenetic alopecia is using 1mg finasteride daily and considering a treatment stack including 0.5mg dutasteride, 2.5mg oral minoxidil, ketoconazole shampoo, Alpecin caffeine shampoo, and RU58841. He seeks advice on the safety and effectiveness of these treatments and whether any adjustments are needed.
community A Logical, Step-by-Step Guide to Managing Androgenetic Alopecia (No BS)
Finasteride and minoxidil are recommended as first-line treatments for hair loss, with dutasteride and oral minoxidil as stronger options if needed. Hair transplants should only be considered after achieving stability with medication, and non-surgical options are suggested if medications are ineffective.
community Female 37/F - On Meds, but no progress. Add PRP?
A 37-year-old woman with androgenetic alopecia is using spironolactone, oral and topical minoxidil, and considering PRP therapy due to lack of progress. She is unable to obtain finasteride, dutasteride, or bicalutamide and is exploring other options like Clascoterone and RU58841.
community Any experience with dutasteride 2.5mg dose? (Or any dose more than 0.5 mg).
A user with aggressive androgenic alopecia is considering increasing their dutasteride dose from 0.5 mg to potentially 2.5 mg, while already using oral minoxidil, Nizoral, RU-58841, and dermapen. They are seeking advice on the effectiveness and side effects of higher dutasteride doses, with suggestions to consult a dermatologist and consider a higher Nizoral concentration.
community Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)
Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.
Related Research
6 / 6 resultsresearch Female Pattern Hair Loss: An Overview with Focus on the Genetics
This review discusses the genetic differences between male and female pattern hair loss and highlights the uncertainty surrounding genetic factors in female pattern hair loss, but reports no clinical results.
research Hair loss and herbs for treatment
This review summarizes causes and treatments of androgenetic alopecia with a focus on herbs as potential alternatives, but reports no new results and suggests more research is needed to validate these options.
research Comparative Evaluation of the Clinical Efficacy of PRP-Therapy, Minoxidil, and Their Combination with Immunohistochemical Study of the Dynamics of Cell Proliferation in the Treatment of Men with Androgenetic Alopecia
This study found that combining platelet-rich plasma therapy with minoxidil was more effective in treating androgenetic alopecia in men than either treatment alone.
research The hydroxypropyl‐β‐cyclodextrin‐minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia
This study in rats found that a new hydroxypropyl-β-cyclodextrin formulation of minoxidil reduced the adverse cardiovascular and proliferative effects seen with traditional minoxidil solutions.
research Distinct Conditions Support a Novel Classification for Bradykinin-Mediated Angio-Oedema
This study found multiple factors, both inherited and acquired, that may lead to bradykinin-mediated angio-oedema, proposing a new classification based on bradykinin production and catabolism imbalance.
research Antiandrogens and Androgen Inhibitors
This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.